[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anterior-myocardial-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anterior-myocardial-infarction":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100616482",false,"NCT07306182","A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction","A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of SGC001 Injection in Chinese Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction and Planned for Primary Percutaneous Coronary Intervention (pPCI)","Inclusion Criteria:\n\n1. 18-79 years of age (including boundary values), male or female;\n2. Anterior wall STEMI: (a) history of persistent chest pain\u002Fprecordial discomfort (\\>30 minutes); (b) upon admission, the ECG must meet the Anterior wall STEMI requirements:\n3. Planned for pPCI treatment;\n4. Assessed as being able to complete dosing within 6 hours of the onset of persistent chest pain\u002Fprecordial discomfort symptoms;\n5. The participant or their legal guardian fully understands the objectives, nature, methods, and potential adverse reactions of the study, voluntarily agrees to participate, and has signed the informed consent form (ICF).\n\nExclusion Criteria:\n\n1. History of the following cardiac conditions:\n\n   1. History of myocardial infarction, coronary revascularization (including percutaneous coronary intervention \\[PCI\\] and coronary artery bypass grafting \\[CABG\\], etc.);\n   2. History of cardiopulmonary resuscitation;\n   3. History of stroke;\n   4. Presence of severe cardiac structural abnormalities such as aortic dissection, and ventricular aneurysm (including new-onset ventricular aneurysm);\n2. Patients who have received thrombolysis;\n3. Patients with a life expectancy of less than 1 year;\n4. Febrile infection requiring systemic treatment within 2 weeks prior to screening;\n5. Left bundle branch block (QRS duration ≥0.12 seconds. Broad R waves in leads V5 and V6, with a notch or slurring at the top, and no preceding q wave. Broad S waves or rS patterns in leads V1 and V2. T waves in leads V5 and V6 are opposite in direction to the main QRS wave);\n6. Cardiogenic shock or hemodynamic instability;\n7. Concomitant severe arrhythmia (including high-degree atrioventricular block, sick sinus syndrome, sustained ventricular tachycardia, etc.) or implanted cardiac pacemaker;\n8. Definitive diagnosis of acute cardiac failure (Killip classification ≥ III; for details on Killip classification, see Appendix);\n9. Unable to undergo cardiac magnetic resonance (CMR) imaging according to the study protocol, or known allergy to any radiocontrast agent;\n10. Participation in other drug clinical trials and use of other investigational drugs within 3 months before receiving the study drug;\n11. Concomitant history of the following serious diseases:\n\n    1. Severe hepatic or renal insufficiency (e.g., requiring dialysis);\n    2. Malignant tumor or history of malignant tumor;\n    3. Severe autoimmune disease requiring therapeutic intervention;\n12. Men and women of childbearing potential (WOCBP) who are fertile and have plans to conceive during the study period, as well as pregnant or lactating women;","ALL","18 Years","79 Years",{"count":19,"type":20},210,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The research study is being done to see if SGC001 can be used to treat people scheduled to undergo percutaneous coronary intervention for Anterior ST-segment Elevation Myocardial Infarction. SGC001 might reduce the infarct size and inhibited inflammation, thereby preventing the incidence of major adverse cardiovascular events(MACE) events. Participants will either get SGC001 (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting SGC001 or placebo is the same. The participant was administered intravenously once. SGC001 is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe.",[26],"Anterior Myocardial Infarction","RECRUITING","2026-05-18",{"date":30,"type":31},"2026-05-19","ACTUAL",{"date":33,"type":31},"2026-03-09",{"date":35,"type":20},"2027-06",{"name":37,"class":38},"Beijing Sungen Biomedical Technology Co., Ltd","INDUSTRY",1,{"id":41,"slug":42,"hasResults":10,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":39},"100584290","tactic-coronary-thrombus-aspiration-with-cath-rx-in-anterior-myocardial-infarction-a-randomized-control-trial-100584290","NCT06887413","TACTIC Coronary Thrombus Aspiration With Cath Rx In Anterior Myocardial Infarction: A Randomized Control Trial.","TACTIC","INCLUSION CRITERIA\n\n1. Age \\>18 and \\\u003C75 years old\n2. Acute anterior STEMI with ≥2 mm in two (2) or more contiguous anterior leads or ≥4 mm total ST-segment deviation sum in the anterior leads V1-V4 AND anterior wall motion abnormality noted on a diagnostic quality left ventriculogram or echocardiogram\n3. Culprit lesion proximal or mid LAD at coronary angiography\n4. TIMI thrombus grading \\> 3 or TIMI flow 0 after guidewire crossing the lesion.\n5. Patient presents to the hospital between 1 - 6 hours of ischemic pain onset\n6. Patient indicated for primary percutaneous coronary intervention (PPCI)\n\nEXCLUSION CRITERIA\n\n1. Unable to give Informed consent.\n2. Life expectancy \\\u003C 1 year.\n3. Contraindication to PCI\n4. STEMI due to stent thrombosis\n5. Spontaneous coronary aretery dissection\n6. Patient undergone any kind of maneuvers to restore flow before randomization\n7. Unwitnessed cardiac arrest OR ≥30 minutes of cardiopulmonary resuscitation (CPR) prior to enrolment OR any cardiac arrest with impairment in mental status, cognition or any global or focal neurological deficit\n8. New onset of stroke symptoms and NIHSS \\>2, prior to index procedure\n9. Known intolerance to aspirin, clopidogrel, ticagrelor, heparin, contrast media.\n10. Active severe bleeding\n11. Severe hepatic\u002Fkidney impairment\n12. Administration of fibrinolytic therapy within 24 hours prior to enrolment\n13. Cardiogenic shock defined as systemic hypotension (systolic BP \\\u003C90 mmHg or the need for inotropes\u002Fpressors to maintain a systolic BP \\>90 mmHg), plus one (1) of the following: any requirement for pressors \u002F inotropes prior to arrival at the catheterization laboratory, clinical evidence of end-organ hypoperfusion, or use of IABP or any other mechanical circulatory support device\n14. Inferior STEMI or suspected right ventricular failure\n15. Severe valvulopathy\n16. Acute cardiac mechanical complication: LV-free wall rupture OR interventricular septum rupture OR acute mitral regurgitation\n\nMedical Conditions \\& History:\n\n1. Suspected or known pregnancy\n2. Suspected systemic active infection\n3. History or known hepatic insufficiency prior to catheterization\n4. Undergoing a renal replacement therapy\n5. Chronic obstructive pulmonary disease (COPD) with home oxygen therapy or on chronic steroid therapy\n6. Contraindication to perform MRI or use gadolinium \\[creatinine clearance (CrCl) \\\u003C30 mL\u002Fmin, non-compatible implant, claustrophobia\\]\n\nCardiovascular history\n\n1. Known or evidence of prior MI, including pathologic Q-waves in non-anterior leads\n2. Prior coronary artery bypass graft surgery (CABG) or LAD PCI\n3. History of heart failure (documented history of EF \\\u003C40% or documented hospitalization for HF within 1 year prior to screening\n4. Prior aortic valve surgery or TAVR\n5. Left bundle branch block (new or old)\n6. History of stroke\u002FTIA within 3 months prior to screening","75 Years",{"count":49,"type":20},140,[51],"NA","The aim of this study is to evaluate the impact of sustained thrombectomy with INDIGO ASPIRATION SYSTEM using CAT RX versus no thrombectomy during primary percutaneous coronary intervention (PPCI) on microvascular obstruction and infarct size, as measured by cardiovascular magnetic resonance (CMR) between 3 and 5 days post PPCI, in patients with anterior STEMI",[26],[55,56,57,58,59,60],"STEMI","thromboaspiration","anterior myocardial infarction","INDIGO CAT RX","indigo system","HEART ATTACK","2026-04-16",{"date":63,"type":31},"2026-04-21",{"date":65,"type":31},"2026-02-18",{"date":67,"type":20},"2027-05-31",{"name":69,"class":38},"Ceric Sàrl"]